Bevacizumab and ranibizumab in exudative age-related macular degeneration: Is the effectiveness conditioned by accessibility?

LUNA J.D; REAL J.P; URRETS-ZAVALIA J.A; PALMA SD; GRANERO, G

INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE

ASSOC RESEARCH VISION OPHTHALMOLOGY INC

Lugar: Rockville, MD 20852; Año: 2013 vol. 54 p. 3798 - 3798

0146-0404

urpose: To evaluate different accessibilities to NV-AMD treatment in clinical practice and estimate their impact on therapeutic effects and visual outcome.Methods: A retrospective analysis of the charts of 78 patients (96 eyes) with previously untreated exudative AMD, who were treated with ranibizumab (RNB) or bevacizumab (BVZ) between January 2009 and December 2011, was conducted. The main outcomes measured included time delay and change in mean best-corrected visual acuity (BCVA) between diagnosis and treatment, annual mean number of injections and follow-up examinations and the major clinical outcomes (mean BCVA change and proportion of patient who lost 15 letters) at 1 year of follow-upResults: Both studied groups showed a statistically significant reduction in BCVA (p